Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice

Current therapies fail to cure over a third of osteosarcoma patients and around three quarters of those with metastatic disease. “Smac mimetics” (also known as “IAP antagonists”) are a new class of anti-cancer...

Source: BMC Cancer - September 14, 2019 Category: Cancer & Oncology Authors: Tanmay M. Shekhar, Ingrid J. G. Burvenich, Michael A. Harris, Angela Rigopoulos, Damien Zanker, Alex Spurling, Belinda S. Parker, Carl R. Walkley, Andrew M. Scott and Christine J. Hawkins Tags: Research article Source Type: research